title: Oral submucous fibrosis: a review of the current management and possible directions for novel therapies.
abstract: This literature review addresses the attempted interventions for the management of oral submucous fibrosis. The literature supports the use of several medical interventions, including micronutrients, antioxidants, proteolytic enzymes, immune modulators (mainly steroids), and agents to promote blood flow. However, the numbers of reported randomized controlled trials are limited. Therefore, no recommendation can be made for any specific intervention. Until now, no single molecular pathway has been identified that is either necessary or sufficient for the development of fibrosis. This has been a bar for any molecular-targeted therapies. Because areca nut (an ingredient of betel quid) plays a major etiologic role in oral submucous fibrosis, cessation of areca nut use remains pivotal in the management of this disorder.
authors.affiliation: King's College London, WHO Collaborating Centre for Oral Cancer, London, UK. Electronic address: S.warne@kcl.ac.uk.
authors.forename: Saman
authors.initials: S
authors.lastname: Warnakulasuriya
authors.affiliation: New York University College of Dentistry, New York, NY, USA.
authors.forename: A Ross
authors.initials: AR
authors.lastname: Kerr
mesh_terms: D001114:Areca / Q000009:adverse effects*; D005544:Forecasting; D006801:Humans; D009914:Oral Submucous Fibrosis / Q000139:chemically induced* / Q000628:therapy*